BioSpace News Archive

Iktos and Astrogen announced that the companies have entered into a research collaboration agreement aimed at discovery of innovative small molecule pre-clinical drug candidates for Parkinson’s disease.

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, announced a partnership with Dutch Leiden University Medical Center to develop and evaluate a new nasal spray corona vaccine in a clinical phase I/II study.

Atom Bioscience announced the close of a $45 million Series C financing round to support a global Phase III clinical trial of ABP-671, the company’s lead small molecule drug for hyperuricemia and gout, and preclinical and clinical development of other pipeline products.

ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, announced the appointment of Hubert C. Chen, M.D. as Chief Medical Officer.

MannKind Corporation announced that has extended its collaboration with Thirona Bio, Inc. with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported the acquisition of its INQUIRE™ Chemical Library to enhance the company’s synthetic lethality drug discovery platform.

Alzheon, Inc. announced that Martin Tolar, MD, PhD, the company’s Founder, President and Chief Executive Officer will present at the H.C. Wainwright Bioconnect Conference on January 10th.

Affimed N.V. announced that its Chief Executive Officer Dr. Adi Hoess will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. Eastern Standard Time / 16:30 Central European Time.

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the year ended December 31, 2021.

Progenity, Inc. announced that two presentations with patient data on indicators of efficacy in the treatment of gastrointestinal disorders have been accepted by the 17th Congress of the European Crohn’s and Colitis Organisation, February 16-19, 2022, the world’s largest forum for IBD specialists.